6 assets in Hereditary Breast Carcinoma

Therapeutic assets addressing Hereditary Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Olaparib Hereditary Breast Carcinoma	Okayama University	P2	B (60)
Carboplatin Hereditary Breast Carcinoma	Okayama University	P2	CCC (53)
Pembrolizumab Hereditary Breast Carcinoma	Okayama University	P2	CCC (53)
tng348 Hereditary Breast Carcinoma	Tango Therapeutics, Inc.	P1/2	CC (47)
Dostarlimab Hereditary Breast Carcinoma	University of Washington	P1	CC (43)
Niraparib Hereditary Breast Carcinoma	University of Washington	P1	CC (43)